

Jordan R Hansford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1308834/publications.pdf>

Version: 2024-02-01

117
papers

5,869
citations

159585

30
h-index

82547

72
g-index

123
all docs

123
docs citations

123
times ranked

8468
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
2	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, 153-165.	1.2	28
3	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	1.2	9
4	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, 997-1007.	1.2	72
5	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
6	Radiomics – A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology. <i>Neuro-Oncology</i> , 2022, , .	1.2	2
7	Characteristics of children ≥36 months of age with DIPG: A report from the international DIPG registry. <i>Neuro-Oncology</i> , 2022, 24, 2190-2199.	1.2	4
8	DIPG-25. Patterns of cerebrospinal fluid diversion and survival in children with diffuse intrinsic pontine glioma: a report from the International Diffuse Intrinsic Pontine Glioma Registry. <i>Neuro-Oncology</i> , 2022, 24, i23-i24.	1.2	0
9	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	1.2	0
10	ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.. <i>Neuro-Oncology</i> , 2022, 24, i6-i7.	1.2	1
11	IMMU-08. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: efficacy, safety, biomarker, and pharmacokinetic results from Checkmate 908. <i>Neuro-Oncology</i> , 2022, 24, i82-i83.	1.2	3
12	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. <i>Neuro-Oncology</i> , 2022, 24, i101-i102.	1.2	0
13	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. <i>Neuro-Oncology</i> , 2022, 24, i117-i117.	1.2	0
14	FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with <i>RAF</i>-altered recurrent or progressive low-grade glioma or advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS10062-TPS10062.	1.6	4
15	Phase I results of the INFORM2 combination study of nivolumab and entinostat in children and adolescents: INFORM2 NivEnt.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10034-10034.	1.6	0
16	Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2052-2052.	1.6	0
17	Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in <i>BRAF</i> V600 mutant pediatric low-grade glioma (pLGG).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA2002-LBA2002.	1.6	35
18	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44

#	ARTICLE	IF	CITATIONS
19	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
20	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
21	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
22	Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children's Oncology Group (ANZCHOG) Study. <i>Frontiers in Oncology</i> , 2021, 11, 660172.	2.8	1
23	An institutional audit of the use of novel drugs in pediatric oncology. <i>Cancer Reports</i> , 2021, , e1404.	1.4	1
24	Growth hormone and targeted oncological agents: Are we stopping children with brain tumours from reaching their true height potential?. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 1170-1174.	0.8	0
25	Clinical Utility of Precision Medicine in Pediatric Oncology: A Systematic Review. <i>JCO Precision Oncology</i> , 2021, 5, 1088-1102.	3.0	14
26	RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2021, 23, i42-i42.	1.2	0
27	An unexpected disease course for a patient with diffuse midline glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29205.	1.5	0
28	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	7.7	36
29	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
30	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	5.6	12
31	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
32	CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi73-vi74.	1.2	1
33	INNV-43. MORE THAN WHAT MEETS THE EYE: ETMR AN UNDER RECOGNISED ATYPICAL BRAINSTEM PRIMARY. A RARE BRAIN TUMOR CONSORTIUM (RBTC) STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi114-vi115.	1.2	0
34	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	7.7	65
35	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. <i>Nature Medicine</i> , 2020, 26, 1742-1753.	30.7	185
36	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	28.9	93

#	ARTICLE	IF	CITATIONS
37	Recurrent <i>SPECC1L</i> – <i>NTRK</i> fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005710.	1.2	4
38	Bevacizumab for pediatric radiation necrosis. <i>Neuro-Oncology Practice</i> , 2020, 7, 409-414.	1.6	9
39	Preoperative chemotherapy in medulloblastoma: a change in treatment paradigm?. <i>Neuro-Oncology</i> , 2020, 22, 1562-1563.	1.2	0
40	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. <i>Acta Neuropathologica</i> , 2020, 140, 765-776.	7.7	23
41	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	1.2	0
42	Treatment response of CNS high-grade neuroepithelial tumors with <i>MN1</i> alteration. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28627.	1.5	5
43	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62
44	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	1.2	51
45	Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28228.	1.5	17
46	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
47	Intracranial growing teratoma syndrome (iGTS): an international case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2020, 147, 721-730.	2.9	21
48	MBRS-54. POOR SURVIVAL IN REPLICATION REPAIR DEFICIENT HYPERMUTANT MEDULLOBLASTOMA AND CNS EMBRYONAL TUMORS: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii407-iii407.	1.2	1
49	“Balancing Expectations with Actual Realities” Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. <i>Journal of Personalized Medicine</i> , 2020, 10, 9.	2.5	20
50	ATRT-08. A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii277-iii277.	1.2	0
51	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii445-iii446.	1.2	0
52	RARE-15. EARLY PSEUDOPROGRESSION POST-RADIATION IN PAEDIATRIC HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY: TWO CASE REPORTS FROM A SINGLE CENTRE. <i>Neuro-Oncology</i> , 2020, 22, iii444-iii445.	1.2	1
53	PATH-01. MOLECULAR PROFILING OF PAEDIATRIC CENTRAL NERVOUS SYSTEM TUMOURS IN AUSTRALASIA – AN UPDATE ON THE AIM BRAIN AND MNP2.0 PROJECTS. <i>Neuro-Oncology</i> , 2020, 22, iii424-iii424.	1.2	0
54	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN’S HAEMATOLOGY/ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii315-iii315.	1.2	0

#	ARTICLE	IF	CITATIONS
55	DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii301-iii302.	1.2	0
56	DIPG-55. PATTERNS OF CEREBROSPINAL FLUID DIVERSION AND SURVIVAL IN CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii297-iii298.	1.2	0
57	MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii394-iii394.	1.2	0
58	MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii401-iii402.	1.2	0
59	DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW. <i>Neuro-Oncology</i> , 2020, 22, iii295-iii296.	1.2	0
60	PATH-09. SJMB12 CLINICAL TRIAL: DISCREPANCY BETWEEN LOCAL AND CENTRAL PATHOLOGY IN ASSESSING ANAPLASTIC MEDULLOBLASTOMA – REPORT FROM A SINGLE SITE EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii426-iii426.	1.2	0
61	RARE-50. TREATMENT RESPONSE OF CNS HIGH-GRADE NEUROEPITHELIAL TUMORS WITH MN1 ALTERATION. <i>Neuro-Oncology</i> , 2020, 22, iii453-iii453.	1.2	0
62	HGG-20. DIAGNOSTIC AND BIOLOGICAL ROLE OF METHYLATION PATTERNS IN REPLICATION REPAIR DEFICIENT HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii347-iii348.	1.2	0
63	MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS. <i>Neuro-Oncology</i> , 2020, 22, iii408-iii408.	1.2	0
64	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	1.2	0
65	Report of a bi-allelic truncating germline mutation in TP53. <i>Familial Cancer</i> , 2019, 18, 101-104.	1.9	3
66	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
67	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
68	DIPG-36. CLINICAL, RADIOLOGICAL, AND HISTO-MOLECULAR CHARACTERISTICS OF DIFFUSE INTRINSIC PONTINE GLIOMA IN PATIENTS WHO SURVIVE LESS THAN 3 MONTHS FROM DIAGNOSIS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2019, 21, ii76-ii77.	1.2	0
69	GENE-04. ESTABLISHING A MOLECULAR PROFILING SERVICE FOR CHILDREN’S CENTRAL NERVOUS SYSTEM TUMORS IN AUSTRALASIA – THE AUSTRALIAN AND NEW ZEALAND CHILDREN’S HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG) AIM BRAIN PROJECT. <i>Neuro-Oncology</i> , 2019, 21, ii81-ii81.	1.2	0
70	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, vi184-vi185.	1.2	0
71	PDTM-24. PNEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, vi192-vi192.	1.2	0
72	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation – Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	7.0	128

#	ARTICLE	IF	CITATIONS
73	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	1.2	0
74	Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma. <i>Cancer Medicine</i> , 2019, 8, 40-50.	2.8	41
75	International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2019, 141, 253-263.	2.9	30
76	Personalised medicine in paediatric oncology: Ethical practice outside the clinical trial framework?. <i>Journal of Paediatrics and Child Health</i> , 2019, 55, 10-12.	0.8	8
77	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
78	GERM-23. INTRACRANIAL GROWING TERATOMA SYNDROME (IGTS): AN INTERNATIONAL RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, i88-i88.	1.2	0
79	31 Intracranial growing teratoma syndrome (IGTS): An international retrospective study. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, S13-S13.	0.5	0
80	HGG-20. DNA METHYLATION ANALYSIS OF HIGH-GRADE GLIOMA IN PATIENTS WITH MISMATCH REPAIR DEFICIENCIES. <i>Neuro-Oncology</i> , 2018, 20, i92-i93.	1.2	0
81	Rare Embryonal Brain Tumours. , 2018, , 289-316.		5
82	DIPG-69. CHARACTERISTICS OF PATIENTS ≥ 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	1.2	1
83	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0
84	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	7.7	118
85	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i72-i73.	1.2	0
86	Spinal Cord Hyperintensities in Neurofibromatosis Type 1: Are They the Cord Equivalent of Unidentified Bright Objects in the Brain?. <i>Pediatric Neurology</i> , 2018, 86, 63-65.	2.1	6
87	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600E mutant relapsed refractory low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10506-10506.	1.6	17
88	Genomic landscape of pineoblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2028-2028.	1.6	0
89	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, e38-e45.	7.0	358
90	Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e32-e37.	7.0	157

#	ARTICLE	IF	CITATIONS
91	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. <i>Clinical Cancer Research</i> , 2017, 23, e107-e114.	7.0	91
92	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	7.7	271
93	Abstract NG05: TP53-mediated human cancer susceptibility is defined by epigenetic dysregulation of microRNA-34A. , 2017, , .		0
94	PNR-33MOLECULAR RE-EVALUATION OF INSTITUTIONALLY DIAGNOSED CNS-PNETS: CLINICAL CONSEQUENCES OF CONFINED DIAGNOSTIC GROUPS. <i>Neuro-Oncology</i> , 2016, 18, iii13.2-iii13.	1.2	1
95	PNR-05PRIMITIVE MYXOID MESENCHYMAL TUMOUR OF INFANCY “ A CASE OF EARLY CHEMOTHERAPY-RESPONSIVENESS AND REVIEW OF THE LITERATURE. <i>Neuro-Oncology</i> , 2016, 18, iii7.5-iii8.	1.2	1
96	HG-53HYPERMUTATION AND NEOANTIGEN FORMATION PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii59.2-iii60.	1.2	0
97	LG-15RISK ASSESSMENT IN PAEDIATRIC GLIOMA - TIME TO MOVE ON FROM THE BINARY CLASSIFICATION. <i>Neuro-Oncology</i> , 2016, 18, iii81.4-iii81.	1.2	0
98	PDCT-09. HYPERMUTATION AND NEOANTIGEN FORMATION IS DIAGNOSTIC AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN CHILDHOOD BIALLELIC MISMATCH REPAIR DEFICIENT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi147-vi147.	1.2	0
99	Central Diabetes Insipidus and Cisplatin-Induced Renal Salt Wasting Syndrome: A Challenging Combination. <i>Pediatric Blood and Cancer</i> , 2016, 63, 925-927.	1.5	9
100	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
101	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. <i>Journal of Neuro-Oncology</i> , 2016, 128, 293-302.	2.9	51
102	PNR-40EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES: A UNIQUE NEW CLINICAL ENTITY. <i>Neuro-Oncology</i> , 2016, 18, iii15.2-iii15.	1.2	1
103	Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 17-20.	1.5	19
104	Reply to Comment on: Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 175-175.	1.5	0
105	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in <i>TP53</i>-Associated Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2016, 34, 3697-3704.	1.6	33
106	PNR-39DISTINCT GENE FUSIONS SEGREGATE SUB-CLASSES OF CNS-PNETs. <i>Neuro-Oncology</i> , 2016, 18, iii15.1-iii15.	1.2	0
107	Sa2045 Tumor Spectrum, Diagnostic Tools and Survival in Patients With Biallelic Mismatch Repair Gene Deficiency (BMMRD) Syndrome: Report From the International BMMRD Consortium. <i>Gastroenterology</i> , 2016, 150, S438-S439.	1.3	0
108	Single agent carboplatin for pediatric low-grade glioma: A retrospective analysis shows equivalent efficacy to multiagent chemotherapy. <i>International Journal of Cancer</i> , 2016, 138, 481-488.	5.1	36

#	ARTICLE	IF	CITATIONS
109	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	1.6	692
110	Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 569-572.	1.3	38
111	Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. <i>Cancer</i> , 2015, 121, 4190-4196.	4.1	64
112	A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy. <i>Haematologica</i> , 2014, 99, e156-e158.	3.5	9
113	Cancer in Australian Aboriginal children: Room for improvement. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, 27-32.	0.8	7
114	Efficacy of acute myeloid leukemia therapy without stem-cell transplantation in a child with blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> , 2013, 98, e30-e31.	3.5	5
115	In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. <i>Haematologica</i> , 2013, 98, e38-e39.	3.5	7
116	Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1807-1809.	3.0	15
117	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. <i>Neuro-Oncology Advances</i> , 0, , .	0.7	6